Funding for this research was provided by:
U.S. Food and Drug Administration (HHSF223201810183C)
Received: 17 March 2021
Accepted: 21 July 2021
First Online: 30 July 2021
: All participants provided content for survey participation. This study was reviewed by the University of North Carolina at Chapel Hill Institutional Review Board and was determined to be not human subjects research (20-1401).
: Not applicable.
: ND’s participation in this research was conducted solely as part of academic duties as a member of the faculty at the University of North Carolina at Chapel Hill. ND is a part-time methods consultant to the RADARS System, which was not involved in nor had knowledge of this manuscript. The RADARS System is supported by subscriptions from pharmaceutical manufacturers, governmental and non-governmental agencies for data, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado (United States of America). Subscribers do not participate in data collection nor do they have access to raw data; Denver Health retains exclusive ownership of all data, databases and systems. Employees are prohibited from personal financial relationships with any biopharmaceutical company.